Lack of Influence of Dyspareunia on the Beneficial Effect of Intravaginal Prasterone (Dehydroepiandrosterone, DHEA) on Sexual Dysfunction in Postmenopausal Women

We have previously observed that intravaginal prasterone (dehydroepiandrosterone, DHEA) improved all domains of female sexual dysfunction (FSD). Investigate the influence of moderate/severe pain at sexual activity (dyspareunia) (MSD) at baseline on FSD following prasterone administration. The effect...

Full description

Saved in:
Bibliographic Details
Published in:Journal of sexual medicine 2014-07, Vol.11 (7), p.1766-1785
Main Authors: Labrie, Fernand, Archer, David, Bouchard, Céline, Fortier, Michel, Cusan, Leonello, Gomez, José‐Luis, Girard, Ginette, Baron, Mira, Ayotte, Normand, Moreau, Michèle, Dubé, Robert, Côté, Isabelle, Labrie, Claude, Lavoie, Lyne, Gilbert, Lucy, Martel, Céline, Balser, John
Format: Article
Language:English
Subjects:
Administration, Intravaginal
Adult
Aged
Androgens
Androgens - administration & dosage
Arousal - drug effects
Dehydroepiandrosterone (DHEA)
Dehydroepiandrosterone - administration & dosage
Double-Blind Method
Dyspareunia - complications
Estrogens - therapeutic use
Female
Female Sexual Dysfunction
Humans
Intracrinology
Low Arousal
Low Desire
Menopause
Middle Aged
Nerve fibers
Nerve Fibers - drug effects
Orgasm - drug effects
Postmenopause - drug effects
Prospective Studies
Quality of Life
Sexual Behavior - drug effects
Sexual Dysfunctions, Psychological - drug therapy
Suppositories
Surveys and Questionnaires
Vagina
Vagina - innervation
Vaginal Diseases - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have previously observed that intravaginal prasterone (dehydroepiandrosterone, DHEA) improved all domains of female sexual dysfunction (FSD). Investigate the influence of moderate/severe pain at sexual activity (dyspareunia) (MSD) at baseline on FSD following prasterone administration. The effect of daily administration of prasterone (0, 3.25 mg, 6.5 mg or 13 mg) for 12 weeks on FSD in 215 postmenopausal women with or without MSD at baseline was evaluated in a prospective, randomized, double‐blind, and placebo‐controlled phase III clinical trial. Differences were examined on desire, arousal and orgasm. Comparable benefits were observed in women not having MSD (n = 56) vs. those having MSD (n = 159). The benefits over placebo in prasterone‐treated women for desire, avoiding intimacy and vaginal dryness as well as for the total sexual domain of the MENQOL (Menopause Specific Quality of Life) questionnaire, ranged between 18.0% and 38.2% with P values of
ISSN:1743-6095
1743-6109
DOI:10.1111/jsm.12517